 CAMBRIDGE, Mass., Sept. 10, 2021 GLOBE NEWSWIRE -- Fulcrum Therapeutics, Inc. Nasdaq: FULC, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the grant of an inducement award outside of the Companys 2019 Stock Incentive Plan to Mel Hayes, the Companys newly appointed Chief Commercial Officer. The grant was approved by the Compensation Committee on August 4, 2021 as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635c4. 